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Introduction
The term “neurogenic bladder” encompasses a highly 
heterogeneous patient population with many different 
disease processes and varying clinical manifestations. 
Depending on the level, completeness, and pathophysiology 
behind each neurologic insult, patients with neurogenic 
bladder may have various permutations of storage and 
voiding disorders. Estimates of lower urinary tract 
dysfunction among patients with neurologic disorders 
range from 12–19% in patients after stroke to up to 90% in 
patients suffering from multiple sclerosis (MS) (1).
The management of  neurogenic bladder varies 
depending on the predominant symptoms but may involve 
behavioral modification, clean intermittent catheterization, 
pharmacotherapy, intradetrusor onabotulinumtoxinA 
injections, or major reconstructive surgery including bladder 
augmentation and urinary diversion. Neuromodulation is 
a well-established treatment option for patients with non-
neurogenic overactive bladder and urinary retention who 
have previously failed more conservative therapies, yet its 
applicability to the neurogenic bladder population has only 
recently been examined more in depth. In this article we 
will discuss the outcomes, contraindications, and special 
considerations of sacral and percutaneous tibial nerve 
stimulation (PTNS) in patients with neurogenic lower 
urinary tract dysfunction.
Neuromodulation
History
The development of neuromodulation began with direct 
electrical stimulation of the bladder in the late 1870s. From 
there researchers moved from stimulation of the target 
organ to stimulation of select peripheral and sacral nerves. 
In the early 1980s Tanagho and Schmidt began developing 
an implantable sacral electrode which would provide the 
basis for the concept of sacral neuromodulation (SNM) 
and the InterStim device (Medtronic) (2). Around the 
same time McGuire used traditional Chinese acupuncture 
techniques and found that electrical stimulation of the tibial 
nerve inhibited bladder overactivity thereby providing the 
concept of PTNS. Both SNM and PTNS were approved 
by the FDA for use in non-neurogenic overactive bladder 
in the late 1990s and SNM was later additionally approved 
for non-obstructive urinary retention. The neurogenic 
population was initially excluded from approval because 
it was thought that an intact neural system was necessary 
for efficacy of the devices. Since this time, however, 
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investigators have extrapolated the use of these devices 
to the neurogenic bladder population in several small 
heterogeneous trials (1,3,4).
Physiology
The exact mechanism of action of neuromodulation has not 
been clearly elucidated. In the past neuromodulation was 
thought to act by direct muscle stimulation. However the 
electrical current produced by neuromodulation is below 
the threshold for motor activation, thus this theory is likely 
inaccurate. The current leading hypothesis suggests that 
neuromodulation works by stimulating peripheral somatic 
afferent nerves (C fibers). In SNM the pudendal afferents 
are stimulated and in PTNS the sensory component of 
the tibial nerve is stimulated. Stimulation of the peripheral 
afferent nerve blocks competing abnormal visceral afferent 
signals from the bladder and prevents reflex bladder 
hyperactivity or retention (Figure 1) (1,4-7). However, the 
effects of neuromodulation are not just limited to spinal 
cord reflexes. Functional magnetic resonance imaging 
(MRI) studies demonstrate changes to brain activity in the 
brainstem and limbic systems with SNM and additional 
studies have shown differences in brain activity in acute 
and chronic neuromodulation consistent with sensorimotor 
learning (8,9).
Sacral neuromodulation (SNM)
Description of procedure
SNM placement is performed as a staged procedure in 
order to demonstrate efficacy in the first phase prior 
to permanent implantation in the second phase. In 
the first surgical procedure a tined quadripolar lead is 
Figure 1 During the normal micturition reflex bladder afferent fibers signal fullness to bladder efferent fibers through spinal interneurons 
which are then influenced upon by supraspinal feedback (either negative for inhibition of voiding or positive for initiation of voiding). 
In overactive bladder there is thought to be loss of supraspinal feedback regulating the normal micturition reflex. Neuromodulation is 
postulated to work in the setting of bladder overactivity by activating peripheral somatic afferent nerves (i.e., the pudendal or posterior 
tibial nerve) which in turn inhibit signals from the bladder afferents at the level of the spinal cord and thus disrupt an aberrant micturition 
reflex. Urinary retention is promoted by the guarding and bladder afferent reflexes. Neuromodulation is postulated to work in the setting of 
urinary retention by restoring normal afferent signaling from the bladder in the midbrain and reducing cortical activity which stimulates the 
guarding reflex (1). SNM, sacral neuromodulation.
PTNS
SNM
Posterior tibial 
afferent (+)
Bladder C-fiber afferents (+)
Key:
(−) Inhibition
(+) Activation
Bladder efferent (−)
(−)
(−)
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Pudendal afferent (+)
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percutaneously inserted into the S3 foramen using bony 
landmarks and fluoroscopic guidance. The nerve root 
is stimulated electrically to assess placement. Responses 
indicating proper placement include plantar flexion of the 
ipsilateral toes, contraction of the levator ani muscle causing 
“bellows”, pulling sensation in the rectum, or tingling/
vibratory sensations in the vagina, labia, scrotum or penis. 
After placement the lead is connected to an external pulse 
generator. The patient wears the temporary device for 
approximately 1–2 weeks and has the ability to change the 
stimulation intensity, pulse width, and frequency of the 
pulse generator. If the patient has a 50% improvement or 
greater in symptoms during the trial period then the lead is 
attached to an implantable pulse generator (IPG) and the 
device is fixed into the upper portion of the buttock during 
the second surgical procedure. If the patient did not have a 
50% improvement in symptoms then the lead is removed in 
the second procedure (4,10).
Outcomes
Prior to 2010 the literature examining the use of SNM in 
the neurogenic population was limited by heterogeneous 
patient populations including multiple neurologic diagnoses, 
lack of randomized controlled trials, small sample sizes, 
and short-term follow-up. Since this time, however, the 
literature has shifted somewhat to separate studies based on 
individual neurologic diagnoses and one randomized trial 
to this effect is currently underway (11). Herein, we will 
examine outcomes of SNM in the generalized neurogenic 
population and then go on to discuss efficacy of this therapy 
among patients with specific neurologic disorders.
General
Overall, the data on SNM in the neurogenic population 
is limited to patients with stroke, Parkinson’s disease, MS 
and incomplete spinal cord injury. With these limitations 
in mind, the current literature is generally positive and 
indicates that SNM demonstrates similar efficacy among 
the neurogenic and non-neurogenic populations in terms of 
successful test phase, device implantation, clinical outcomes, 
urodynamic outcomes, quality of life data, and safety among 
carefully selected cases. Per the literature, patients with 
neurologic disorders demonstrate test phase success rates 
that range from 50–68% and implantation success rates 
that range from 80–92%, comparable to implantation 
success rates of 80–90% in the non-neurogenic population 
(3,7,12,13).
Two studies, neither of which defined the severity of the 
neurologic insult, looked at neurogenic overactive bladder 
patients with stroke, Parkinson’s disease, MS, among other 
neurologic conditions, and showed durable decreases in 
frequency, incontinence episodes, and urgency symptoms 
over time. These same patients, however, had significantly 
lower decreases in number of voids per day compared to 
the non-neurogenic population (Medtronic, Minneapolis, 
Minnesota, USA) (1 vs. 3) (13,14). Another study evaluated 
39 patients with neurogenic overactivity due to mixed 
etiologies [primarily representing spinal cord injured 
patients described as American Spinal Injury Association 
(ASIA) C and D, who have higher functional status than 
ASIA A and B individuals], and demonstrated that 43% of 
patients were able to stop their anticholinergic medications 
entirely and 80% of patients reported complete continence 
by bladder diary with SNM (15).
The same study also evaluated 11 highly functional 
spinal cord injured patients with urinary retention and 
found that all subjects were able to void spontaneously after 
device implantation (15). This neurogenic group, along 
with another study involving both complete and incomplete 
spinal cord injured patients, also demonstrated sustained 
improvement in urodynamic parameters with increased 
bladder capacity, improved compliance, and increased 
maximum detrusor pressure (15,16).
While both neurogenic and non-neurogenic groups 
demonstrate statistically significant improvement in most 
quality of life measures after device implantation, those with 
a neurologic diagnoses of stroke, Parkinson’s disease, and 
MS have been shown to have worse baseline physical scores 
that slightly declined in those with progressive disease (13). 
In long-term follow-up among patients with various types of 
neurologic disorders, implant success appeared durable over 
time with 75.7% having continued success at 4 years (14). In 
terms of safety, there did not appear to be any increased risk 
of complications in the neurogenic population (12.9–24% 
neurogenic vs. 33% non-neurogenic) (7,12-14).
While these results may sound promising, it  is 
important to consider the specifics of each publication 
separately before drawing any generalizable conclusions. 
Unfortunately, most studies involving neurogenic patients 
do not include descriptions or indicators of disease severity, 
which makes their interpretation and significance difficult 
to understand. Descriptions of ASIA classification, an 
indicator of the extent and severity of the neurologic insult, 
is imperative to understanding the population studied, 
but is often not provided. For example, a fully ambulatory 
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individual with MS may be expected to have a different 
response to therapy than an individual with MS who uses 
a wheelchair. However, this level of detail is often not 
communicated in the literature. Furthermore, the findings 
of each of the studies discussed herein should be interpreted 
with these limitations in mind.
Multiple sclerosis (MS)
Particular attention has been given to the outcomes of SNM 
in the MS population. This population presents unique 
challenges given the heterogeneity of neurologic lesions (and 
thus symptoms) and the ability of the disease to progress 
over time. Generalized test phase success rates have been 
reported to be approximately 50–84%, comparable to 
success rates in the broader neurogenic bladder population 
(3,7,14,17). Interestingly, while success has not been found 
to correlate with duration of the neurologic disease nor the 
specific urologic symptoms, multiple studies cite significant 
increases in quality of life measures with patient satisfaction 
up to 75–86% (17-19).
One study of 25 individuals with MS (severity of disease 
not described) found that 100% of subjects that failed the 
test phase had symptoms of urinary retention, as opposed 
to overactivity, suggesting that SNM be better utilized for 
treatment of bladder overactivity in this population (17). 
Of those MS subjects with detrusor overactivity, SNM 
has been found to reduce frequency by 6–9 voids per day, 
reduce incontinence by 4–10 episodes per day, and increase 
voided volume by 77–84 mL per void (1,17,19).
In MS subjects with detrusor-sphincter dyssynergia, which 
is not an FDA approved indication for SNM, SNM was 
associated with a significant increase in voids (5–8 per day), 
with increase in voided volume by 154 mL, and with a decrease 
in the number of catheterizations by two per day (17).
Another study of 14 subjects with MS (of varying types: 
three benign disease, seven relapsing remitting, four 
secondary progressive) and urinary retention found that 
86% of individuals were able to void spontaneously after 
IPG placement with mean post-operative post-void residual 
of 51 mL and max flow rate of 18 mL/s (18). This study 
goes on to suggest that in this population, individuals with 
two or more leads producing bellow or plantar flexion at 
an IPG power rating of six or less have a 76% chance of 
success.
Failure rates due to disease progression ranged from 
16–33% with follow-up extending 0.5–4.3 years (1,4-
7,19). One study found that failures occurred on average 
approximately 12 months after SNM placement (14). Two 
studies found slightly lower mean battery life 5–6.1 years in 
the MS population which could potentially be due to higher 
amplitude usage as the disease progresses, ultimately leading 
to an increase in revision rates (17,18).
Patients with neurologic disease or injuries that have 
the potential to change over time, such as MS, need to 
understand that their SNM device may lose efficacy as the 
natural history of their disease progresses. Additionally, 
the need for possible MRI imaging should be taken into 
account prior to considering SNM placement in these 
individuals. Some authors recommend proceeding with 
SNM only in the relapsing-remitting MS subtype who has 
not experienced any relapse for 2 years who are not likely to 
require repeated MRI scans (3,7,12-14,19).
Spinal cord lesions
Similar to the literature on MS, the outcomes of SNM in 
individuals with spinal cord lesions are quite difficult to 
interpret based on the population studied. The majority 
of studies combine both incomplete and complete lesions 
from a variety of etiologies, lack descriptions of the extent 
and severity of disease or only include the least severe 
patients (classified as ASIS C or D), and are thus highly 
heterogeneous. Overall, success rates range from 29–70%, 
depending on the study and the population examined 
(7,13,14,20,21).
One meta-analysis found that patients with any type of 
spinal cord lesion demonstrated a test phase success rate 
of 35% (range, 29–44%), depending on the type of lesion 
(success rates were 29%, 40%, and 44% for incomplete, 
complete, and unknown types of lesions) (7,15). They 
further found that the success rates of the permanent 
implant at time of last follow-up was 77%, which was 
lower than in the success rate for all types of neurogenic 
bladder combined (92%). Again success is this population 
was variable and depended on the type of spinal cord lesion 
(success rates were 83%, 81%, and 58% for incomplete, 
complete, and unknown types of lesions) (7,14). This study 
demonstrated high inter-study heterogeneity combined 
with a lack of detail on disease severity, and results should 
be interpreted with this in mind.
One study of 85 patients with incomplete spinal cord 
injuries (73% traumatic, 25% myelitis, 3% vascular) and 
non-obstructive urinary retention demonstrated a test 
phase success rate of 43% and these patients subsequently 
underwent permanent IPG placement. Of note, this study 
was restricted to higher functioning patients, classified 
as ASIA C or D. After the test phase in subjects with 
121Translational Andrology and Urology, Vol 5, No 1 February 2016
Transl Androl Urol 2016;5(1):117-126tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
retention, 22 additional subjects (26%) were able to void 
spontaneously with a significant increase in maximum 
flow rate and a significant decrease in post-void residual. A 
significant predictor of successful first stage response was 
the first sensation of bladder filling (47% vs. 13%, P=0.02) 
on urodynamics. Thirty-four patients had adequate follow-
up and of those 67.6% achieved consistent success with the 
permanent implant. The remaining third of patients had a 
least one or more “failures” during follow-up that required 
contralateral or S4 implantation. After re-implantation all 
patients subsequently improved both subjectively and on 
urodynamics. Of the failures, one occurred before 3 years, 
five occurred between 3–5 years and the remaining seven 
occurred after 5 years. The cause of failure was often 
not known, with displacement of the lead representing a 
minority of cases. The author suggested “nerve fatigue” as 
a possible source of failure as all subjects who failed their 
initial implants achieved amelioration of symptoms with a 
new contralateral implant (20).
Another study incorporated 23 individuals with mostly 
incomplete (91%) spinal cord injuries from various 
heterogeneous etiologies (myelomeningocele: 9, incomplete 
SCI: 7, spina bifida: 3, complete SCI: 2, resection of cord 
tumor: 1, intravertebral anesthetic complication: 1), ASIA 
classification not reported. This study found that test phase 
success rate of 56.5%. They found that test phase outcomes 
correlated best with symptoms, as patients with urgency-
frequency or urinary incontinence had better outcomes 
(65%, 70% respectively) than those with dysuria (29%). 
A significant positive predictor of test phase success was 
lower volume at first sensation of bladder filling on baseline 
urodynamic parameters (361 vs. 421 mL at baseline) and 
a non-significant negative predictor was a complete spinal 
cord lesion (21). Ultimately they performed an implant 
in 13 patients (five of which had incomplete spinal cord 
injuries, six had myelomeningocele, one had spina bifida, 
and one had post resection of spinal cord tumor) and had 
a permanent implant success rate of 92.3% at 17.5 months 
of follow-up. Patients experienced significant reduction in 
number of voids, episodes of urgency and degree in urgency 
with increase in volume per void (21).
Interestingly, recent work supported by Medtronic, the 
company who makes InterStim, or sacral neuromodulators, 
has shown potential utility of early SNM during the spinal 
cord shock phase after complete spinal cord lesions to T2-
11, ASIA A classification. This study compared ten subjects 
who elected to undergo bilateral SNM within 4.5 months 
of injury to six similarly injured subjects in a control group. 
At a mean of 26.2 months of follow-up, individuals in the 
SNM group had favorable findings compared to those in the 
control group, despite use of pharmacotherapy in the latter 
group. Namely, no individuals in the SNM group developed 
detrusor overactivity on urodynamics, poor compliance with 
detrusor pressures over 30 cmH2O, or urinary incontinence. 
Additionally, the SNM group demonstrated decreased 
infection rates, better quality of life, and improved erectile 
and bowel function. These results are intriguing and need 
to be reproduced in a larger more vigorous trials prior to 
being utilized en mass (22).
Spinal surgery
A retrospective review examined the use of SNM for 
approved indications in 32 individuals who had undergone 
spinal surgery at various levels (67% performed for disc 
disease) and compared outcomes to 102 non-neurogenic 
controls. Sixty-three percent of neurogenic subjects 
had a successful test phase and underwent permanent 
implantation compared to 75% of the control group. When 
comparing groups based on urinary symptoms, there were 
similar test phase outcomes except in the setting of urgency 
urinary incontinence, wherein the neurogenic group was 
significantly less likely to undergo a permanent implant 
(58.8% vs. 89.5%, P=0.002). Explantation rates and time 
to explantation were similar between neurogenic and non-
neurogenic populations (23).
Cerebral palsy
A limited number of studies, mostly case reports, have 
examined the use of SNM in patients with cerebral palsy 
(13,14,24,25). Test phase success rates and implant success 
rates are very high (100% for both), however, these results 
are based on small case numbers and are in very well selected 
ambulatory patients with minimal medical co-morbidities 
and good sensation on urodynamic testing (7,25).
Relative and absolute contraindications
While SNM may be effective in a select group of 
more functional neurologic patients with overactive 
bladder symptoms and urinary retention, there are 
several indications where SNM is not approved or is 
contraindicated. SNM has not been shown to be effective for 
stress incontinence or mixed urinary incontinence (5,17-19). 
Additionally, older age has been shown to be associated 
with lower rates of efficacy. In patients with urgency urinary 
incontinence in both the neurogenic and non-neurogenic 
populations, subjects over the age of 55 had lower cure rates 
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(defined as no pads per day) compared to younger subjects 
(65% vs. 37%, P<0.05 in non-neurogenic, 56% vs. 29% in 
neurogenic). Also, both younger and older patients with 
more than three co-morbidities had a decreased chance of 
cure (defined as no pads per day) (17,26). One study looked 
at SNM in various neurogenic populations and found that 
non-ambulatory patients have worse outcomes (18,25). 
Additionally, significant spinal abnormalities or contractures 
may lead to difficult lead placement and pressure on IPG 
may cause or exacerbate sacral decubitus ulcers.
SNM should not be performed in pregnant women due 
to theoretical risk of fetal loss or preterm labor. MRI of the 
abdomen or pelvis is contraindicated due to concerns of 
device dislodgement, heating of the electrodes and changes 
to the program due to the magnetic fields. New studies have 
demonstrated that head-only 1.5 tesla MRI examinations can 
be safely performed with newer generation IPG models (27,28).
Additional benefits
SNM additionally appears to have a positive effect on both 
bowel and erectile function. One study of six individuals 
with incomplete spinal cord lesions with both urgency 
urinary and fecal incontinence responded positively to 
SNM with all regaining fecal continence post-operatively 
in addition to significant improvements in bladder diary 
and urodynamic findings. Two subjects with baseline 
constipation as well as lower urinary tract dysfunction had 
50% improvement in bowel symptoms after implantation. 
Finally six individuals undergoing SNM implantation for 
neurogenic urinary retention had erectile dysfunction 
managed with oral medications. Post-implantation the 
average Sexual Health Inventory for Men (SHIM) scores 
improved from 15.2 to 22 and all subjects were able to stop 
oral erectile dysfunction medications (29).
Percutaneous tibial neuromodulation (PTNS)
Description of procedure
PTNS is an alternative neuromodulation modality for 
patients who may not be good candidates for or who may 
not want to undergo SNM. There are several variations 
on how to perform the needle placement. One such 
variation is with the patient sitting in a frog-leg position 
with the knees flexed and the soles of the feet touching. 
A 34-gauge stainless steel needle is inserted three 
fingerbreadths cephalad from the medial malleolus and 
just one fingerbreadth posterior to the margin of the tibia 
at an angle of 60 degrees. The needle is advanced 3–4 cm 
posterior to the tibia. A stick-on electrode is placed on 
the medial surface of the calcaneus or on the bottom of 
the foot. A stimulator is connected to the needle and to 
the grounding pad. The needle is stimulated and proper 
placement is demonstrated by either a sensory (tingling 
sensation in ankle, foot or toes) or motor response (great 
toe flexion and/or fanning or plantar toe flexion of toes 2 
through 5) (30).
Stimulation is titrated based on patient pain. Therapeutic 
sessions are typically once per week for 12 weeks. If patients 
have a good response they are offered maintenance therapy. 
One study found that in individuals with MS the presence of 
a sensory response, either with or without a motor response 
during stimulation, was associated with a better treatment 
outcome (P=0.001) and that the interval maintenance 
needed was every 2 weeks in 60% of subjects (4,31,32).
Outcomes
General
As in SNM, the literature reports of PTNS in the 
neurogenic bladder population is complicated by limited 
number of studies, small sample sizes, non-standard 
treatment plans, poor descriptions of the extent and 
severity of neurologic disease, and heterogeneous patient 
populations. With this in mind, a recent meta-analysis 
examined the success of PTNS in a variety of different 
patient populations, including MS and Parkinson’s 
disease, with mixed findings on success rates ranging from 
approximately 40% to 100% for neurogenic overactive 
bladder or urinary retention (33). The broad ranges of 
success are confounded by varying neurogenic patient 
populations and differing definitions of success used in 
each study, including clinical, urodynamic or quality of 
life parameters. Another study examined urodynamic 
outcomes in a mostly neurogenic population with detrusor 
overactivity (MS: 13, spinal cord injury: 15, Parkinson’s: 9, 
idiopathic: 7) and determined that PTNS caused a delay 
in onset of involuntary detrusor contractions by 69 mL 
during the filling phase and an increase in bladder capacity 
by 56 mL and was considered to be “positive” in 50% of 
patients (34).
Multiple sclerosis (MS)
The majority of PTNS research in neurogenic bladder has 
focused on the MS population. As previously described, this 
population is unique in that patients have mixed urologic 
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diagnoses including detrusor over-activity, detrusor-
sphincter dyssynergia, or detrusor underactivity. One 
study looked at 18 individuals with MS and lower urinary 
tract symptoms (LUTS) treated with PTNS. Ten (54%) 
had relapsing remitting, seven had secondary progressive 
and one had primary progressive disease. No patients had 
signs of peripheral neuropathy. At 3-month follow-up 
89% of subjects were subjectively pleased with the results 
[assessed via patient perception of bladder condition (PPBC) 
questionnaire and visual analogue scale]. Decreases in 
urinary incontinence were not statistically significant. Of 
note, one patient with advanced disability from secondary 
progressive MS and another patient with relapsing remitting 
MS without disability and detrusor sphincter dyssynergia 
showed no response to treatment (35).
Another study of 70 ambulatory MS patients who were 
free from MS relapse during the preceding 3 months and 
who had refractory overactive bladder symptoms were 
treated with PTNS. Specifically, 82.6% of subjects cited 
improved urgency, 51.3% reported resolution of urgency, 
66.7% reported improved frequency, 62% reported 
improved continence, and 44.9% reported resolution 
of incontinence. Quantitatively subjects on average 
experienced 2–6 fewer daytime voids, 2–3 fewer night-time 
voids, and 2.7 fewer incontinence episodes per week. These 
findings correlated with average increased voided volumes 
by 43–89 mL and decreased post-void residuals by 16– 
55 mL (36).
While some studies have reported increased bladder 
capacity and increased volume at signs of the first detrusor 
contraction, these findings have not been duplicated across 
studies nor do they appear to be associated with patient 
subjective response (36-38). One study of MS patients with 
all types of disease (51% relapsing remitting) suggested that 
despite good initial outcomes, these results improve over 
time with overall symptom improvement increasing from 
70% at 6 months to 82% at 24 months (32).
Parkinson’s disease
There is limited research on PTNS in the Parkinson’s 
disease population. Two studies for which incomplete 
data are available examined outcomes in 6 and 29 subjects, 
respectively, and found 83–89% improvement in subjective 
symptoms based on standardized patient questionnaires 
(39,40). Of note, one of the studies combined patients 
with Parkinson’s disease and multiple system atrophy 
(MSA). Other studies report improvement in urodynamic 
parameters with a 49–96 mL improvement in bladder 
capacity and 100 mL increase in volume before the first 
detrusor contraction (39,41).
Stroke
While there is only one study examining the use of PTNS 
in the setting of stroke, it is one of the few examples of a 
randomized clinical trial in this literature. In this trial 24 
adult male subjects with neurogenic overactive bladder due 
to ischemic stroke were randomized to either PTNS twice 
weekly for 6 weeks versus general advice and stretching for 
6 weeks. Compared to the controls, the PTNS treatment 
arm experienced non-significant decreases in urgency (by 
25%), urgency urinary incontinence (by 8%), nocturnal 
enuresis (by 17%), and nocturia (by 33%). Treatment 
arm individuals additionally had a significant decrease 
in daytime frequency and significant improvement in 
subjective symptom scores compared to the control group. 
These results were maintained at 12 months of follow-up. 
The authors additionally concluded that patients with right 
hemisphere lesions, advanced age and high body mass index 
(BMI) had more urinary symptoms than other patients (42). 
It is important to remember that while these results sound 
promising, they include a very small number of participants 
and overall the findings were not statistically better than 
general advice and stretching.
Spinal cord injury
Only one recently published study has examined the 
use of PTNS in spinal cord injury patients. This study 
randomized 100 individuals to either PTNS or solifenacin. 
The majority of spinal cord lesions in this cohort were 
described as “complete”; however, ASIA classification was 
not reported. At 2 weeks there was a statistically significant 
improvement in the examined parameters of volume per 
catheterization, leakage per day, and quality of life in both 
the PTNS and solifenancin groups, but importantly, there 
was no statistically significance between treatment groups. 
While the treatment results were similar between groups, 
PTNS was noted to be more tolerable than pharmacologic 
management, as 5% of the solifenacin group experienced 
side effects and two subjects discontinued the trial for this 
reason (43).
Relative and absolute contraindications
Absolute contraindications for PTNS therapy include 
patients with pacemakers, implantable defibrillators, 
coagulopathy, or who are pregnant (44). In the non-
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neurogenic population, patients with worse obstructive 
symptoms, detrusor overactivity on urodynamics, and poor 
mental health scores on the SF-36 are associated with poor 
treatment outcomes (33).
Special considerations
PTNS may be a more suitable neuromodulation treatment 
choice in the MS population as this population is likely to 
need future MRI imaging and may potentially have disease 
progression for which a permanent implant may no longer 
be efficacious. PTNS is additionally a good alternative to 
SNM in patients with skeletal abnormalities preventing 
appropriate placement of the sacral neurostimulator.
Conclusions
While the current literature is optimistic about the use of 
SNM and PTNS in the neurogenic population, it is also 
complicated by a limited number of studies, small sample 
sizes, non-standard treatment plans, poor descriptions of 
patient populations and the extent and severity of neurologic 
disease, and heterogeneous patient populations. Further 
studies with larger sample sizes, better disease classification, 
and more vigorous study designs are warranted before 
more widespread use of these treatment modalities can be 
enthusiastically recommended.
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